New Stratigidies in Therapeutics: Hypolipidemic Agents

Review Article

Austin Pharmacol Pharm. 2019; 4(1): 1019.

New Stratigidies in Therapeutics: Hypolipidemic Agents

Murad S1*, Iftikhar S2, Arain AQ3, Mastoi MI4, Ghaffar A5, Seema6 and Murad JS7

1Professor of Pharmacology, IMDC, Islamabad, Pakistan

2Associate Prof of Pharmacology at RLMC, Lahore, Pakistan

3Associate Professor of Pharmacology at HBS Medical College, Islamabad-Pakistan

4PRO, PARC, Islamabad-Pakistan

5SWO at LMDC/DANTH, Islamabad Pakistan

6Gynecologist at NMC, Karachi, Pakistan

7Psychology Deptt at BU, Karachi, Pakistan

*Corresponding author: Murad S, Professor of Pharmacology, IMDC-Islamabad, Pakistan

Received: August 05, 2019; Accepted: September 10, 2019; Published: September 17, 2019


High lipid accumulation and biomass productivity are the two manifestly desired phenotypes in algae for biodiesel production. However, various studies conducted under nutrient depleted conditions have demonstrated that biomass productivity and lipid accumulation are negatively related. These studies have established that stress conditions, which by definition reduce the biomass production, increase lipid content of algae. This problem was addressed by using a two-stage reactor where algal species such as Oocysti sp. and amphora sp. are grown in optimal conditions for maximum biomass, followed by stress conditions for maximum lipid accumulation. Within this context, nitrogen depletion can be still considered as a strategy for increasing lipid accumulation since it has been still defined as one of the best lipid accumulator stress condition in algae to date. However, the mechanistic insights of this phenomenon are still needed. Hyperlipidemia especially LDL-cholesterol may lead to development of coronary artery disease causing morbidity or mortality due to cardiac arrhythmias. Conventional hypolipidemic drugs have unwanted effects. Herbal therapy for Hyperlipidemia is getting attention due to their less frequent side effects. In this study, we have compared hypolipidemic effects of Gemfibrozil with Nigella sativa. Seventy-five hyperlipidemic patients from Jinnah Hospital Lahore were enrolled for study. After getting consent all patients were divided in three groups comprising 25 patients in each group. Group 1 was on Nigella sativa, group 2 was on Gemfibrozil and third group was on placebo therapy. They were advised to take drugs for two months. After completion of study pretreatment and post, treatment values of LDL cholesterol were analyzed statistically. In Nigella sativa group LDL cholesterol decreased from 191.14±3.45 to 159.40±2.98mg/dl, means 31.7mg/dl LDL reduction was observed when compared with placebo group (Table 1). In Gemfibrozil group of patients LDL cholesterol decreased from 197.77±3.91mg/dl to 159.62±2.20mg/dl, means LDL reduction in mean values was 38.2mg/dl (Table 2), when compared with placebo group. These changes are highly significant with p-values of ‹0.001. We concluded from this study that herbal medicine Nigella sativa is as effective as traditionally used hypolipidemic drug Gemfibrozil.